《大行報告》匯豐研究降普拉達(01913.HK)目標價至61元 評級「買入」
匯豐研究發表報告,普拉達(01913.HK)去年表現強勁,零售額的自然增長是同業中最佳,今年繼續跑贏同業,相信明年及2025年仍然展示堅實的趨勢。
該行預期,以固定匯率計算,明年普拉達的零售額增長10%,達到50億歐元,2025及2026年預測銷售額分別56億及60億歐元。今年上半年毛利率80.3%,已屬同業中最高水平,但仍然繼續提升,主要受惠銷售渠道組合改善、亞洲銷售佔比增加、促銷網點減少及原價銷售佔比提升。
該行將普拉達目標價由65元下調至61元,主要因爲該行調整歐元對港元的匯率預測,維持其「買入」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.